Friberg Gregory R's Form 4 filing
Biomarin Pharmaceutical IncBMRN · filed Feb 26, 2026
- Accession no.
- 0001628280-26-012539
- Filed
- Feb 26, 2026
- Trade date
- Feb 26, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $382.0K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Friberg Gregory RCIK 0002038768 | Officer (EVP, Chief R&D Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | Common Stock | SSaleDisposed | −6,326 | $60.38F1 | −$381,963.88 | 37,578 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price in column 4 is the weighted average price. The purchase price actually received ranged from $60.36 to $60.51. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price
Referenced by the price of 1 transaction in Table I.